Screening Libraries

Proteins

NH2-PEG2-methyl acetate hydrochloride

Cat. No.: HY-W096162A CAS No.: 208647-73-8 Molecular Formula: C₇H₁₆CINO₄ Molecular Weight: 213.66

PROTAC Linkers Target:

Pathway: **PROTAC**

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

H-CI

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (468.03 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.6803 mL	23.4017 mL	46.8033 mL
	5 mM	0.9361 mL	4.6803 mL	9.3607 mL
	10 mM	0.4680 mL	2.3402 mL	4.6803 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (11.70 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (11.70 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	${\tt NH2-PEG2-methyl\ acetate\ is\ a\ PEG-based\ PROTAC\ linker\ that\ can\ be\ used\ in\ the\ synthesis\ of\ PROTACs}^{[1]}.$
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com